NCT01887379View on ClinicalTrials.gov

Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Gastroretentive Drug Formulation of FurosemideOedema

Interventions

DRUG

GRDF furosemide

The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.

Trial Locations (1)

10578

SocraTec R&D GmbH Clinical Pharmacology Unit, Berlin